Aspergillus tracheobronchitis after allogeneic bone marrow transplantation
Recently Machida et al 1 presented in this journal a case of a patient with an Aspergillus tracheobronchitis after allogeneic BMT together with a review of the literature of this serious complication after BMT. We would like to add our recent experience and comment on the role of galactomannan antigen testing in establishing the diagnosis of this Aspergillus infection.
A 56-year-old female patient underwent allogeneic BMT in our center after induction of first complete morphological and cytogenetic remission of acute myeloid leukemia. After conditioning with idarubicin, cyclophosphamide and busulfan, bone marrow-derived stem cells from her histocompatible sibling were infused. She developed grade II acute GVHD of the skin, for which she was treated with prednisone. Later on she experienced grade IV chronic GVHD of the gastro-intestinal tract and three episodes of CMVcolitis. Treatment with high-dose corticosteroids, cyclosporin, ganciclovir and CMV-hyperimmunoglobulins was given with limited success. On day 193 after BMT she was admitted to our hospital because of severe dyspnea, inspiratory wheezing and hoarseness. Temperature was not raised and persistent severe diarrhea was still present. Physical examination showed severe respiratory distress with use of accessory respiratory muscles and extreme inspiratory wheezing, and on auscultation her breath sounds were hardly audible. Chest X-ray and high-resolution CT scan were unremarkable. Lung function examination demonstrated extreme inspiratory and expiratory obstruction. Yellowish plaques, ulcerations and pseudomembranes were seen on bronchoscopy performed immediately and there were mucus plugs that almost completely obstructed the trachea and bronchi. Microscopic examination of the obstructing material showed hyphae and cultures yielded Aspergillus fumigatus. Biopsy was considered impossible because of the low platelet count. Daily bronchial flushing and treatment with high-dose amphotericin B (1 mg/kg/day, 45 mg daily) and nebulized amphotericin B was started with only temporary improvement. Liposomal amphotericin B 200 mg daily and itraconazole (200 mg, twice daily for 2 days, followed by 200 mg daily) as well as G-CSF (300 g daily) were added without any improvement. Our patient became ventilator-dependent and could no longer cope with this regime. For this reason it was decided to abstain from further treatment and she died of respiratory failure the same day, 37 days after admission. Permission for autopsy was denied.
Like Machida et al 1 we measured serum galactomannan antigen levels by ELISA (Platelia Aspergillus; Sanofi Diagnostics Pasteur, Marnes-la-Coquette, France). In a series of six consecutive serum samples, the highest galactomannan serum ratio found was 0.6 which is below the recommended cut-off level of 1.0. This observation might have several explanations. Firstly, Clarke et al 2 divided fungal tracheobronchitis into two different morphological types. The first type is characterized by intraluminal growth involving the entire circumference of the airway with only superficial invasion and ulceration; tenacious mucus or Bone Marrow Transplantation fungus plugs are present. The second type comprises one or more plaques restricted to a relatively small portion of the tracheobronchial tree. This type is more invasive, leading eventually to pulmonary hemorrhage. Circulating antigen may be detected only when tissue invasion by fungal hyphae takes place. Although we could not establish the degree of invasion because biopsy material was lacking, the evidence suggests that our patient had the first, non-invasive type. This would explain the absence of gallactomannan. Alternatively, false negative ELISA reactivity could account for the findings in our patient. Sensitivity of the test used by Machida et al 1 and ourselves varied between 67 and 100% in different studies. 3 A recent report by Maertens et al 4 showed a percentage of false-negatives of 4.5% in a group of patients with proven invasive aspergillosis. The authors did not mention the presence of Aspergillus tracheobronchitis in their patient group. Therefore we conclude that, whichever is the case, the use of this test in confirming Aspergillus tracheobronchitis seems limited.
The review of Machida et al 1 and the outcome in our patient suggests that tracheobronchitis caused by Aspergillus infection after BMT is uniformly lethal. However, one of two additional patients reported as case reports in the literature survived. These cases were found by a Medline search using the keywords 'endobronchial aspergillosis'. Angelucci el al 5 reported two patients with Aspergillus tracheobronchitis after allogeneic BMT for thallassemia. A 15-year-old boy developed this species of aspergillosis while already being treated with high-dose amphotericin B and died of massive lung involvement. The second patient, an 18-year-old man, survived the obstructing localized bronchial aspergillosis after aggressive removal of obstructing material by rigid bronchoscope and forceps, increasing the dose of previously started amphotericin B, adding treatment with flucytosine and nebulized amphotericin B. He was, at the time, recovering from post-BMT aplasia. Thus it seems that surviving tracheobronchial aspergillosis after allogeneic BMT might be possible provided that the patient can withstand the vigorous regime required to remove all the infected material. 5% false negatives in a group of patients with proven invasive aspergillosis. However, the sensitivity of the blood test was reported to vary widely from 67 to 90%. [1] [2] [3] We presume that the blood tests detecting circulating fungal components may be insensitive in some patients with invasive aspergillosis. In our experience, sensitivities of the blood tests are influenced by the distribution of invasive aspergillosis. In our institutions, the sensitivities of the latex agglutination test detecting galactomannan antigen, which is less sensitive than enzyme-linked immunosorbent assay, and the beta-dglucan assay were 75 and 63%, respectively, in patients with disseminated invasive aspergillosis. However, the value decreased to 13 and 38%, respectively, in patients with localized invasive aspergillosis.
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